Evotec (ETR:EVT) Trading 2.4% Higher – Time to Buy?

Evotec SE (ETR:EVT) shares traded up 2.4% on Tuesday . The stock traded as high as €4.91 and last traded at €4.88. 641,418 shares changed hands during mid-day trading, a decline of 53% from the average session volume of 1,360,000 shares. The stock had previously closed at €4.77.

Evotec Stock Up 2.4%

The company has a debt-to-equity ratio of 55.38, a quick ratio of 2.97 and a current ratio of 1.68. The stock has a market cap of $906.20 million, a price-to-earnings ratio of -5.28, a PEG ratio of 0.98 and a beta of 1.30. The firm’s 50-day simple moving average is €5.04 and its two-hundred day simple moving average is €5.34.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer, as well as a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic.